Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 Study of Telisotuzumab Adizutecan (ABBV-400) With or Without Osimertinib vs Standard of Care in EGFR-Mutated NSCLC After Third-Generation EGFR TKI
jRCT2031250357Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of telisotuzumab adizutecan in Non-small cell lung cancer (NS-NSCLC) (6 arms), sponsored by AbbVie Inc. Primary endpoints: Objective Response Rate (Phase 2, BICR, RECIST v1.1) and Progression-Free Survival (Phase 3, BICR, RECIST v1.1). Started Jan 2026; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on jRCT2031250357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250357.